BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical
Ceruvia Lifesciences Submits FDA Investigational New Drug Application for NYPRG-101 Migraine Prevention Program Based on
How to Change Your Mind | Official Trailer | Netflix The most famous book on
Ceruvia Lifesciences to Supply LSD to Qualified Researchers at No Cost For qualified researchers only…
MindMed Collaborators Announce Positive Topline Data from Phase 2 Trial Evaluating LSD in Anxiety Disorders
Mycrodose Therapeutics Successfully Delivers Both Macro and Microdose Levels of Psilocin Using Core Drug Delivery
Blackhawk’s MindBio Therapeutics Announces Completion of World First Phase 1 Microdosing Clinical Trial Successful completion
BetterLife To Present BETR-001 Preclinical Data at the Upcoming Canadian Association for Neuroscience Conference VANCOUVER,
GoDaddy Billionaire Bob Parsons Believes Psychedelics Can Heal Trauma—And He’s Putting His Money (And Brain)
MindMed Collaborator Dr. Matthias Liechti to Present Topline Clinical Trial Results for LSD in Anxiety
Delic Labs Receives Health Canada 56 Exemption to Conduct Research on MDMA, LSD and Other
Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample A
Blackhawk’s MindBio Therapeutics Enters its 80th and Final Patient into Phase 1 Clinical Trials and
Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission
BetterLife Obtains In Vivo PK Data for BETR-001 Confirming its Bioavailability in Brain VANCOUVER, British
Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety Novamind (NM) announced that
Blackhawk’s MindBio Therapeutics Invests NZ$2.3 Million to Fast Track Psychedelic Microdosing Phase 2 Clinical Trials
MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin
The Nobel Prize-Winning, LSD Dropping, Yet Problematic Scientist Who Invented PCR LSD led to the
Psilocybin use associated with lowered odds of having been arrested, study finds People who use
Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism This week, Nova Mentis (NOVA)
BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity in Preclinical Model VANCOUVER, British Columbia, Feb.
Fish on acid? Microdosing zebrafish with LSD shows its potential benefits for humans New research suggests
FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder MindMed’s LSD-based compound
